DPH Insider Trading

Insider Ownership Percentage: 9.29%
Insider Buying (Last 12 Months): £5,017.35
Insider Selling (Last 12 Months): GBX 0

Dechra Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Dechra Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Dechra Pharmaceuticals Share Price & Price History

Current Price: GBX 0
Price Change: +0.30 (1.20%)
As of 01/16/2024 10:23 PM ET

This chart shows the closing price history over time for DPH up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Dechra Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/15/2024Ian PageInsiderBuy155GBX 3,237£5,017.35
10/12/2022Lisa BrightInsiderBuy585GBX 2,558£14,964.30
10/7/2022John ShipseyInsiderBuy600GBX 2,529£15,174
9/22/2022Paul SandlandInsiderSell1,936GBX 2,781£53,840.16
4/5/2022Alison PlattInsiderBuy2,346GBX 4,230£99,235.80
10/5/2021Paul SandlandInsiderSell3,960GBX 4,828£191,188.80
9/21/2021Tony GriffinInsiderSell5,346GBX 5,237£279,970.02
9/10/2021Tony GriffinInsiderSell17,500GBX 5,001£875,175
See Full Table

SEC Filings (Institutional Ownership Changes) for Dechra Pharmaceuticals (LON:DPH)

105.51% of Dechra Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Dechra Pharmaceuticals logo
Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, internal medicine, and nutrition products supporting cats and dogs with various therapeutic conditions, such as allergies, obesity, heart, and kidney diseases. It also provides water soluble antibiotics, vaccines, lameness, pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies. In addition, the company distributes veterinary pharmaceuticals and equipment; markets pet diets; and develops, regulates, manufactures, and markets crop protection, as well as offers financial services. It markets its products through wholesaler and distributor networks. The company operates in the United Kingdom, Germany, rest of Europe, the United States, and internationally. Dechra Pharmaceuticals PLC was incorporated in 1997 and is headquartered in Northwich, the United Kingdom.
Read More on Dechra Pharmaceuticals

Today's Range

Now: N/A

50 Day Range

MA: GBX 3,866
Low: 3,866
High: 3,866

52 Week Range

Now: N/A

Volume

2,044,628 shs

Average Volume

1,290,707 shs

Market Capitalization

£4.40 billion

P/E Ratio

N/A

Dividend Yield

1.20%

Beta

0.78

Who are the company insiders with the largest holdings of Dechra Pharmaceuticals?

Dechra Pharmaceuticals' top insider investors include:
  1. Ian Page (Insider)
  2. John Shipsey (Insider)
  3. Lisa Bright (Insider)
  4. Paul Sandland (Insider)
Learn More about top insider investors at Dechra Pharmaceuticals.